Zyklophin is a semisynthetic peptide derived from dynorphin A and a highly selective antagonist of the κ-opioid receptor (KOR).[1][2] It is systemically-active, displaying good metabolic stability and blood-brain-barrier penetration.[2] Similarly to other KOR antagonists, it has been shown to block stress-induced reinstatement of cocaine-seeking in animals.[2] The drug is currently experimental, and thus cannot be considered safe for consumption or usage.
See also
References
- ^ Patkar KA, Yan X, Murray TF, Aldrich JV (July 2005). "[Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist". J. Med. Chem. 48 (14): 4500–3. doi:10.1021/jm050105i. PMID 15999987.
- ^ a b c Aldrich JV, Patkar KA, McLaughlin JP (October 2009). "Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action". Proc. Natl. Acad. Sci. U.S.A. 106 (43): 18396–401. doi:10.1073/pnas.0910180106. PMC 2775281. PMID 19841255.